Table 4 Statistical values and distribution of drug-induced cataract.
From: Pharmacovigilance of drug-induced cataract using the FDA Adverse Event Reporting System
Drug | Classification | Number | ROR (95%CI) | PRR (95%CI) | MGPS (95%CI) | BCPNN (95%CI) | PRR (X2) | P value |
|---|---|---|---|---|---|---|---|---|
Difluprednate | Glucocorticoids | 7 | 890.02(397–1995.27) | 751.72(751.04–752.41) | 749.23(381.29–1472.23) | 9.55(7.83–11.27) | 751.72(5231.72) | < 0.001 |
Prednisolone | Glucocorticoids | 3 | 413.34(127.03–1345.01) | 380.79(379.7–381.88) | 380.25(141.68–1020.52) | 8.57(6.84–10.3) | 380.79(1134.99) | < 0.001 |
Dexamethasone | Glucocorticoids | 18 | 96.92(60.66–154.84) | 95.04(94.58–95.5) | 94.24(63.67–139.47) | 6.56(4.89–8.23) | 95.04(1660.92) | < 0.001 |
Mometasone | Glucocorticoids | 13 | 44.2(25.56–76.43) | 43.81(43.26–44.35) | 43.54(27.53–68.86) | 5.44(3.78–7.11) | 43.81(540.54) | < 0.001 |
Methylprednisolone | Glucocorticoids | 8 | 27.86(13.88–55.89) | 27.7(27.01–28.4) | 27.6(15.41–49.43) | 4.79(3.12–6.46) | 27.7(205.17) | < 0.001 |
Triamcinolone | Glucocorticoids | 31 | 18.63(13.06–26.58) | 18.56(18.21–18.92) | 18.3(13.6–24.64) | 4.19(2.53–5.86) | 18.56(507.65) | < 0.001 |
Fluticasone furoate | Glucocorticoids | 39 | 12.46(9.08–17.12) | 12.44(12.12–12.75) | 12.22(9.37–15.94) | 3.61(1.94–5.28) | 12.44(402.61) | < 0.001 |
Erdafitinib | Antineoplastic Agents | 3 | 144.67(45.84–456.55) | 140.48(139.37–141.6) | 140.29(53.63–366.98) | 7.13(5.44–8.82) | 140.48(414.97) | < 0.001 |
Ibrutinib | Antineoplastic Agents | 3 | 7.41(2.39–23.01) | 7.4(6.27–8.53) | 7.39(2.86–19.08) | 2.89(1.22–4.55) | 7.4(16.59) | < 0.005 |
Rituximab | Antineoplastic Agents | 5 | 6.66(2.77–16.03) | 6.65(5.78–7.53) | 6.64(3.18–13.84) | 2.73(1.06–4.4) | 6.65(23.97) | < 0.001 |
Insulin lispro | Insulin | 5 | 105.39(43.4–255.89) | 103.16(102.29–104.03) | 102.92(48.99–216.19) | 6.69(5.01–8.36) | 103.16(504.75) | < 0.001 |
Insulin human | Insulin | 16 | 10.59(6.47–17.33) | 10.57(10.08–11.06) | 10.5(6.95–15.85) | 3.39(1.72–5.06) | 10.57(137.66) | < 0.001 |
Insulin glargine | Insulin | 25 | 5.95(4.01–8.83) | 5.95(5.55–6.34) | 5.89(4.23–8.19) | 2.56(0.89–4.22) | 5.95(101.67) | < 0.001 |
Dorzolamide | Antiglaucoma Preparations | 3 | 117.62(37.39–370.02) | 114.84(113.72–115.96) | 114.68(43.95–299.2) | 6.84(5.15–8.53) | 114.84(338.13) | < 0.001 |
Latanoprost | Antiglaucoma Preparations | 13 | 66.79(38.57–115.65) | 65.9(65.35–66.44) | 65.5(41.37–103.69) | 6.03(4.36–7.7) | 65.9(825.9) | < 0.001 |
Pomalidomide | Immunosuppressants | 3 | 9.71(3.13–30.18) | 9.7(8.57–10.83) | 9.68(3.75–25) | 3.28(1.61–4.94) | 9.7(23.37) | < 0.001 |
Cyclosporine | Immunosuppressants | 27 | 3.43(2.35–5.01) | 3.43(3.05–3.81) | 3.4(2.47–4.67) | 1.76(0.1–3.43) | 3.43(45.82) | < 0.001 |
Nitisinone | Alimentary Tract And Metabolism | 12 | 53.91(30.47–95.37) | 53.32(52.76–53.89) | 53.03(32.9–85.47) | 5.73(4.06–7.4) | 53.32(612.72) | < 0.001 |
Ranibizumab | Antineovascularisation Agents | 23 | 46.98(31.09–71) | 46.54(46.13–46.95) | 46.04(32.59–65.04) | 5.52(3.86–7.19) | 46.54(1013.93) | < 0.001 |
Pentosan polysulfate | Glycosaminoglycans | 5 | 13.67(5.68–32.92) | 13.64(12.76–14.51) | 13.61(6.52–28.38) | 3.77(2.1–5.43) | 13.64(58.42) | < 0.001 |
Hydroxychloroquine | Antimalarials | 4 | 9.59(3.59–25.61) | 9.58(8.6–10.56) | 9.56(4.2–21.74) | 3.26(1.59–4.93) | 9.58(30.68) | < 0.001 |
Pamidronic acid | Bisphosphonates | 4 | 6.4(2.4–17.08) | 6.39(5.41–7.37) | 6.38(2.81–14.51) | 2.67(1.01–4.34) | 6.39(18.17) | < 0.001 |
Tiotropium | Anticholinergics | 3 | 5.64(1.82–17.51) | 5.63(4.5–6.77) | 5.63(2.18–14.52) | 2.49(0.82–4.16) | 5.63(11.42) | < 0.01 |
Atorvastatin | Statins | 10 | 5.3(2.85–9.88) | 5.3(4.68–5.92) | 5.28(3.14–8.88) | 2.4(0.73–4.07) | 5.3(34.73) | < 0.001 |
